Stockreport

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Scleros...

Chemomab Therapeutics Ltd. - American Depositary Shares  (CMMB) 
PDF —Clinical Data from Phase 2 SPRING Trial Shows that CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Prim [Read more]